Pritha Roy Choudhury
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Pritha Roy Choudhury has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Jayanta Chakrabarti
Department of Surgical Oncology, Chittaranjan National Cancer Institute, Kolkata, West Bengal, India
1 shared publication - Prodipto Das
Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute (CNCI), Kolkata 700026, India
1 shared publication - Saptak Banerjee
Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India
1 shared publication - Shontol Bhowmic
Department of Surgical Oncology, Chittaranjan National Cancer Institute (CNCI), Kolkata 700026, India
1 shared publication - Subir Kumar Juin
Department of Zoology, University of Calcutta, 35 Ballygunge Circular Road, Kolkata 700019, India
1 shared publication - Sweta Ghosh
Department of Microbiology and Immunology, UofL-Brown Cancer Center, Center for Microbiomics, Inflammation and Pathogenicity, University of Louisville, Louisville, USA
1 shared publication
Latest Publications
- Open Access
Gut Microbiota and Microbial Metabolites in the Regulation of Chemotherapeutic Resistance
Resistance to chemotherapy continues to be a significant challenge for cancer treatment and a contributing factor to treatment failures and tumor progression. Recently, the gut microbiome has emerged as an important modulator of the response to chemotherapy. Numerous pre-clinical and clinical studies have demonstrated a direct association between gut microbiota composition and therapy effectiveness in many cancer types, such as colorectal, breast, pancreatic, gastric, and lung cancers, melanoma, and hematological cancers. Gut microbiota effectively regulate the efficiency of chemotherapeutic agents in various ways, either by biotransformation of chemotherapeutic agents or modulation of host immunity. In addition, microbial metabolites such as short-chain fatty acids, secondary bile acids, and tryptophan metabolites are also involved in the regulation of chemotherapy response through modulating apoptosis, immunity, and epithelial–mesenchymal transition. Finally, dysbiosis induced by chemotherapy and antibiotics has also been reported to reduce the effectiveness of therapy. This review will emphasize the ways in which gut microbiota can modulate chemotherapeutic response and induce chemoresistance. Understanding the interactions between chemotherapeutic drugs and the gut microbiota can help to enhance the efficiency of chemotherapy and find more appropriate personalized treatments.
Open AccessGut Microbiota and Microbial Metabolites in the Regulation of Chemotherapeutic Resistance
Resistance to chemotherapy continues to be a significant challenge for cancer treatment and a contributing factor to treatment failures and tumor progression. Recently, the gut microbiome has emerged as an important modulator of the response to chemotherapy. Numerous pre-clinical and clinical studies have demonstrated a direct association between gut microbiota composition and therapy effectiveness in many cancer types, such as colorectal, breast, pancreatic, gastric, and lung cancers, melanoma, and hematological cancers. Gut microbiota effectively regulate the efficiency of chemotherapeutic agents in various ways, either by biotransformation of chemotherapeutic agents or modulation of host immunity. In addition, microbial metabolites such as short-chain fatty acids, secondary bile acids, and tryptophan metabolites are also involved in the regulation of chemotherapy response through modulating apoptosis, immunity, and epithelial–mesenchymal transition. Finally, dysbiosis induced by chemotherapy and antibiotics has also been reported to reduce the effectiveness of therapy. This review will emphasize the ways in which gut microbiota can modulate chemotherapeutic response and induce chemoresistance. Understanding the interactions between chemotherapeutic drugs and the gut microbiota can help to enhance the efficiency of chemotherapy and find more appropriate personalized treatments.